Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

33.33
+3.9013.25%
Post-market: 33.550.2194+0.66%19:49 EST
Volume:3.20M
Turnover:104.14M
Market Cap:2.13B
PE:-8.33
High:34.07
Open:29.10
Low:28.81
Close:29.43
52wk High:51.27
52wk Low:18.53
Shares:63.93M
Float Shares:42.92M
Volume Ratio:2.66
T/O Rate:7.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9990
EPS(LYR):-2.7500
ROE:-73.25%
ROA:-38.12%
PB:5.34
PE(LYR):-12.12

Loading ...

Vera Therapeutics Inc - Origin Phase 3 Trial Meets Primary Endpoint With 46% Reduction

THOMSON REUTERS
·
Nov 08

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 08

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 08

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Nov 07

Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating

TIPRANKS
·
Nov 07

Vera Therapeutics Announces Promising Phase 3 Trial Results

TIPRANKS
·
Nov 06

Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept

TIPRANKS
·
Nov 06

Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy

Reuters
·
Nov 06

Vera Therapeutics Announces Positive Origin Phase 3 Data for Atacicept in Iga Nephropathy Presented at Asn Kidney Week 2025 and Published in the New England Journal of Medicine

THOMSON REUTERS
·
Nov 06

Vera Therapeutics Reports Increased Losses Amid R&D Expansion

TIPRANKS
·
Nov 06

Vera Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

TIPRANKS
·
Nov 06

Vera Therapeutics reports Q3 EPS ($1.26), consensus ($1.13)

TIPRANKS
·
Nov 05

Vera Therapeutics Q3 EPS misses estimates

Reuters
·
Nov 05

Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate

Benzinga
·
Nov 05

BRIEF-Vera Therapeutics Q3 EPS USD -1.26 Vs. IBES Estimate USD -1.17

Reuters
·
Nov 05

Vera Therapeutics reports Q3 net loss of $80.3 million

Reuters
·
Nov 05

Vera Therapeutics Inc: Potential U.S. Commercial Launch of Atacicept in 2026

THOMSON REUTERS
·
Nov 05

Vera Therapeutics Advances IgAN Treatment with Atacicept Study

TIPRANKS
·
Oct 28

Vera Therapeutics to Present ORIGIN Phase 3 Atacicept Data for IgA Nephropathy at ASN Kidney Week 2025

Reuters
·
Oct 22

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

GlobeNewswire
·
Oct 22